THANK YOU FOR SUBSCRIBING
THANK YOU FOR SUBSCRIBING
Once the ADC is inside the cancer cells, the cytotoxic drug payloads are cleaved off or released and subsequently exert their cell-killing effects. At the forefront of this development is Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing ARCs. It uses use internal radiation to fight cancer, by linking a radioactive isotope to the antibody and delivering it to the site of the cancer treatment. The solution can target both solid and other cancers, whether it is a lump in the body or blood cancers where external radiation cannot be used due to their distribution in the bloodstream.We took an idea that was ahead of its time and we believe we are leading the space. In terms of our scientific pedigree, the company is world-class as are the institutions that we continue to work with
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info